Compare Amylx Pharmaceuticals Inc (AMLX) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Lowe`s Companies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Lowe`s Companies Inc trades at $212.03 (market cap $118.66B). The key difference: Lowe`s Companies Inc is far larger — about 59.9× Amylx Pharmaceuticals Inc's market cap, and Lowe`s Companies Inc pays a 2.36% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LOW | |
|---|---|---|
Market Cap | $1.98B | $118.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $287.39 |
52-Week Low | $7.64 | $206.62 |
Enterprise Value | $1.70B | $160.42B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Lowe's Companies (LOW) trades at $211.63, down 0.64% on the day, with a bearish technical signal from moving averages. The company maintains solid fundamentals with a P/E of 17.89 and net income margin of 7.51%, having beaten earnings estimates for three consecutive quarters. Revenue declined to $83.67 billion in 2025 but shows stabilization with 2026 projections of $88.4 billion. Analyst consensus remains strongly bullish with a $260.88 price target, representing 23% upside potential from current levels.
LOW presents a compelling value opportunity with strong dividend growth and consistent earnings performance, though near-term headwinds include housing market sensitivity and competitive pressures. The stock's current valuation discount to analyst targets and improving cash flow trends support a positive medium-term outlook, balanced by technical weakness and macroeconomic uncertainties affecting the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
